Numinus Wellness (NUMI.V) partnered with KGK Science, a contract research organization focusing on natural products, for a few psilocybin extraction clinical trial today, according to a press release. The…
clinical trials
Cybin (CYBN.NE) announced its plans to advance the pre-clinical work for two of its molecules: its orally dissolving tablet (ODT) formulation CYB003 and its inhaled formulation CYB004. These…
“2021 will be transformational for the company as we advance the clinical development of our lead product,” added LeDuc….
Naturally Splendid (NSP.V) has provided an update regarding a Health Canada approved clinical trial and strategic outlook for the development of Cavaltinib™. “We have been working with Franco and…
RAMM Pharma (RAMM.C) has begun its clinical trials studying the efficacy of its proprietary NettaVet pet cannabinoid formulation for the treatment of four pathologies in animals. “We are, from…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…
Algernon Pharmaceuticals (AGN.C) and Charles River Laboratories agreed to have the latter handle Algernon’s DMT pre-clinical studies for their stroke clinical research program today, according to a press release….
Pharmadrug (BUZZ.C) signed a binding letter of intent yesterday to acquire biotech firm, Sairiyo Therapeutics, according to a press release. At present, Sairiyo is working on pushing their lead…
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….